<DOC>
	<DOCNO>NCT00727428</DOCNO>
	<brief_summary>The present study intend assess novel formulation FluLaval . The idea obtain preliminary data safety immune response FluLaval TF influenza vaccine adult . These data serve basis study involve different population . This protocol post deal objective &amp; outcome measure primary phase/study .</brief_summary>
	<brief_title>Immunogenicity Safety GSK Biologicals ' FluLaval® TF</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol Male female adult , 18 60 year age . Written inform consent obtain subject . Satisfactory baseline medical assessment history physical examination ( stable health status exclusionary medical psychiatric condition ) . Access consistent mean telephone contact , may either home workplace , land line mobile , pay phone multipleuser device . Acute disease time enrollment . Significant acute chronic , uncontrolled medical psychiatric illness . `` Uncontrolled '' define : Requiring institution new medical surgical treatment within 1 month prior study enrollment , Requiring reinstitution previously discontinue medication medical treatment within one month prior study enrollment , Requiring change medication dosage one month prior study enrollment due uncontrolled symptom drug toxicity ( elective dosage adjustment stable subject acceptable ) , Hospitalization event fulfil definition SAE within 1 month prior study enrollment . Any confirm suspected immunosuppressive condition include : History human immunodeficiency virus ( HIV ) infection , Cancer treatment cancer , within 3 year study enrollment . History renal impairment . History hepatic dysfunction due hepatitis B , C toxins include alcohol . Complicated insulindependent diabetes mellitus . Unstable cardiopulmonary disease require chronic medical therapy associate functional impairment . Presence blood dyscrasia , include hemoglobinopathy myelo lymphoproliferative disorder . Receipt systemic glucocorticoidswithin 1 month study enrollment , chronic use cytotoxic immunosuppressive drug within six month study enrollment . Inhaled topical steroid allow . History demyelinate disease include Multiple Sclerosis GuillainBarré syndrome . Presence active neurological disorder . History chronic alcohol consumption and/or drug abuse . Any significant disorder coagulation increase risk intramuscular injection treatment coumadin derivative heparin Receipt influenza vaccine 20078 influenza immunization season . Administration vaccine within 30 day prior study enrollment study period . Subjects receive treatment enrollment follow per protocol include safety analysis , exclude accordingtoprotocol cohort . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede vaccination plan use study period . Administration immunoglobulins and/or blood product within 3 month precede administration study vaccine plan study . Any known suspected allergy constituent FluLaval and/or flu vaccine and/or history anaphylactictype reaction consumption egg . A history severe adverse reaction previous influenza vaccination . If subject female , must nonchildbearing potential childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution duration study . Lactating/nursing female . Any condition , opinion investigator , prevents subject participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>FluLaval® TF</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Influenza</keyword>
</DOC>